All In Biotech

Drug Trial Radar · NCT06308978

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

244

Planned (sponsor's estimate)

Start

Mar 28, 2024

Primary completion

Sep 30, 2027

Study completion Sep 30, 2042

Sponsor

Lead sponsor
Fate TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.

Conditions

  • Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
  • Idiopathic Inflammatory Myositis (IIM)
  • Systemic Sclerosis (SSc)
  • Systemic Lupus Erythematosus (SLE)
  • Lupus Nephritis

Interventions

  • FT819Drug

    FT819 will be administered as intravenous (IV) infusion at planned dose levels.

  • FludarabineDrug

    Fludarabine will be administered as an IV infusion at planned dose levels.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered as an IV infusion at planned dose levels.

  • BendamustineDrug

    Bendamustine will be administered as an IV infusion at planned dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to approximately 2 years
  2. Number of participants with serious TEAEsTime frame: Up to approximately 2 years
  3. Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to approximately 29 days

Locations

21 sites in 4 countries. Site status is shown where the registry gives one.

  • Wallace Rheumatic Center

    Beverly Hills, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • University of California Irvine

    Irvine, California · Recruiting

  • Children's Hospital Los Angeles Division Of Rheumatology

    Los Angeles, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • University of Louisville

    Louisville, Kentucky · Recruiting

  • University of Minnesota Medical School

    Minneapolis, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Montefiore Medical Center

    New York, New York · Recruiting

  • Duke University Health System

    Durham, North Carolina · Recruiting

  • MetroHealth

    Cleveland, Ohio · Recruiting

  • University of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • Jefferson Einstein Hospital Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Regional One Health

    Memphis, Tennessee · Recruiting

  • Hôpital La Pitié Salpêtrière

    Paris, France · Recruiting

  • Uppsala University

    Uppsala, Uppland, Sweden · Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • University College of London Hospitals NHS Trust (UCLH)

    London, United Kingdom · Recruiting

  • Manchester University NHS Foundation Trust

    Manchester, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.